Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Pathological Role of Anti-CD4 Antibodies in HIV-Infected Immunologic Nonresponders Receiving Virus-Suppressive Antiretroviral Therapy.

Luo Z, Li Z, Martin L, Wan Z, Meissner EG, Espinosa E, Wu H, Yu X, Fu P, Julia Westerink MA, Kilby JM, Wu J, Huang L, Heath SL, Li Z, Jiang W.

J Infect Dis. 2017 Jul 1;216(1):82-91. doi: 10.1093/infdis/jix223.

2.

Use of an Outreach Coordinator to Reengage and Retain Patients with HIV in Care.

Bean MC, Scott L, Kilby JM, Richey LE.

AIDS Patient Care STDS. 2017 May;31(5):222-226. doi: 10.1089/apc.2016.0318. Epub 2017 May 10.

PMID:
28488904
3.

Actinomyces meyeri, a Common Agent of Actinomycosis.

Rolfe R, Steed LL, Salgado C, Kilby JM.

Am J Med Sci. 2016 Jul;352(1):53-62. doi: 10.1016/j.amjms.2016.03.003. Epub 2016 Mar 18.

PMID:
27432035
4.

Tobacco Use Patterns in a Southern US HIV Clinic.

Bean MC, Richey LE, Williams K, Wahlquist AE, Kilby JM.

South Med J. 2016 May;109(5):305-8. doi: 10.14423/SMJ.0000000000000460.

5.

Key differences in B cell activation patterns and immune correlates among treated HIV-infected patients versus healthy controls following influenza vaccination.

Luo Z, Ma L, Zhang L, Martin L, Wan Z, Warth S, Kilby A, Gao Y, Bhargava P, Li Z, Wu H, Meissner EG, Li Z, Kilby JM, Liao G, Jiang W.

Vaccine. 2016 Apr 7;34(16):1945-55. doi: 10.1016/j.vaccine.2015.12.038. Epub 2015 Dec 22.

6.

Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial.

Walmsley S, Baumgarten A, Berenguer J, Felizarta F, Florence E, Khuong-Josses MA, Kilby JM, Lutz T, Podzamczer D, Portilla J, Roth N, Wong D, Granier C, Wynne B, Pappa K.

J Acquir Immune Defic Syndr. 2015 Dec 15;70(5):515-9. doi: 10.1097/QAI.0000000000000790. Erratum in: J Acquir Immune Defic Syndr. 2016 Jan 1;71(1):e33.

7.

Humoral immune responses to Streptococcus pneumoniae in the setting of HIV-1 infection.

Zhang L, Li Z, Wan Z, Kilby A, Kilby JM, Jiang W.

Vaccine. 2015 Aug 26;33(36):4430-6. doi: 10.1016/j.vaccine.2015.06.077. Epub 2015 Jun 30. Review.

8.

Plasmacytoid dendritic cells mediate synergistic effects of HIV and lipopolysaccharide on CD27+ IgD- memory B cell apoptosis.

Zhang L, Luo Z, Sieg SF, Funderburg NT, Yu X, Fu P, Wu H, Jiao Y, Gao Y, Greenspan NS, Harding CV, Kilby JM, Li Z, Lederman MM, Jiang W.

J Virol. 2014 Oct;88(19):11430-41. doi: 10.1128/JVI.00682-14. Epub 2014 Jul 23.

9.

Microbial TLR Agonists and Humoral Immunopathogenesis in HIV Disease.

Yu X, Li Z, Zhou Z, Kilby JM, Jiang W.

Epidemiology (Sunnyvale). 2013 Feb 2;3:120.

10.

Preventing neonatal transmission of herpes simplex virus.

Jaiyeoba O, Amaya MI, Soper DE, Kilby JM.

Clin Obstet Gynecol. 2012 Jun;55(2):510-20. doi: 10.1097/GRF.0b013e31824defdb. Review.

PMID:
22510634
11.

Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection.

Meditz AL, MaWhinney S, Allshouse A, Feser W, Markowitz M, Little S, Hecht R, Daar ES, Collier AC, Margolick J, Kilby JM, Routy JP, Conway B, Kaldor J, Levy J, Schooley R, Cooper DA, Altfeld M, Richman D, Connick E.

J Infect Dis. 2011 Feb 15;203(4):442-51. doi: 10.1093/infdis/jiq085. Epub 2011 Jan 18.

12.

CD8 T-cell proliferative capacity is compromised in primary HIV-1 infection.

Heath SL, Sabbaj S, Bansal A, Kilby JM, Goepfert PA.

J Acquir Immune Defic Syndr. 2011 Mar 1;56(3):213-21. doi: 10.1097/QAI.0b013e3181ff2aba.

13.

The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection.

Markowitz M, Vaida F, Hare CB, Boden D, Mohri H, Hecht FM, Kalayjian RC, Conrad A, Mildvan D, Aberg J, Hogan C, Kilby JM, Balfour HH Jr, Schafer K, Richman D, Little S.

J Infect Dis. 2010 May 1;201(9):1298-302. doi: 10.1086/651664.

14.

Switching HIV therapies: competing host and viral factors.

Kilby JM.

Lancet. 2010 Jan 30;375(9712):352-4. doi: 10.1016/S0140-6736(10)60067-0. Epub 2010 Jan 12. No abstract available.

PMID:
20074790
15.

Modeling sequence evolution in acute HIV-1 infection.

Lee HY, Giorgi EE, Keele BF, Gaschen B, Athreya GS, Salazar-Gonzalez JF, Pham KT, Goepfert PA, Kilby JM, Saag MS, Delwart EL, Busch MP, Hahn BH, Shaw GM, Korber BT, Bhattacharya T, Perelson AS.

J Theor Biol. 2009 Nov 21;261(2):341-60. doi: 10.1016/j.jtbi.2009.07.038. Epub 2009 Aug 4. Review. Erratum in: J Theor Biol. 2012 Mar 21;297:187.

16.

Gender differences in discontinuation of antiretroviral treatment regimens.

Kempf MC, Pisu M, Dumcheva A, Westfall AO, Kilby JM, Saag MS.

J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):336-41. doi: 10.1097/QAI.0b013e3181b628be.

17.
18.

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection.

Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, Sun C, Grayson T, Wang S, Li H, Wei X, Jiang C, Kirchherr JL, Gao F, Anderson JA, Ping LH, Swanstrom R, Tomaras GD, Blattner WA, Goepfert PA, Kilby JM, Saag MS, Delwart EL, Busch MP, Cohen MS, Montefiori DC, Haynes BF, Gaschen B, Athreya GS, Lee HY, Wood N, Seoighe C, Perelson AS, Bhattacharya T, Korber BT, Hahn BH, Shaw GM.

Proc Natl Acad Sci U S A. 2008 May 27;105(21):7552-7. doi: 10.1073/pnas.0802203105. Epub 2008 May 19.

19.

Treatment response in acute/early infection versus advanced AIDS: equivalent first and second phases of HIV RNA decline.

Kilby JM, Lee HY, Hazelwood JD, Bansal A, Bucy RP, Saag MS, Shaw GM, Acosta EP, Johnson VA, Perelson AS, Goepfert PA; UAB Acute Infection, Early Disease Research Program (AIEDRP) Group.

AIDS. 2008 May 11;22(8):957-62. doi: 10.1097/QAD.0b013e3282fbd1da.

20.

The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.

Mitsuyasu R, Gelman R, Cherng DW, Landay A, Fahey J, Reichman R, Erice A, Bucy RP, Kilby JM, Lederman MM, Hamilton CD, Lertora J, White BL, Tebas P, Duliege AM, Pollard RB; AIDS Clinical Trials Group 328 Study Team.

Arch Intern Med. 2007 Mar 26;167(6):597-605.

PMID:
17389292
21.

Functionally competent antigen-specific CD127(hi) memory CD8+ T cells are preserved only in HIV-infected individuals receiving early treatment.

Sabbaj S, Heath SL, Bansal A, Vohra S, Kilby JM, Zajac AJ, Goepfert PA.

J Infect Dis. 2007 Jan 1;195(1):108-17. Epub 2006 Nov 20.

PMID:
17152014
22.

A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024).

Kilby JM, Bucy RP, Mildvan D, Fischl M, Santana-Bagur J, Lennox J, Pilcher C, Zolopa A, Lawrence J, Pollard RB, Habib RE, Sahner D, Fox L, Aga E, Bosch RJ, Mitsuyasu R; Adult AIDS Clinical Trials Group A5024 Protocol Team.

J Infect Dis. 2006 Dec 15;194(12):1672-6. Epub 2006 Nov 8.

PMID:
17109338
23.

A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.

Hecht FM, Wang L, Collier A, Little S, Markowitz M, Margolick J, Kilby JM, Daar E, Conway B, Holte S; AIEDRP Network.

J Infect Dis. 2006 Sep 15;194(6):725-33. Epub 2006 Aug 15.

PMID:
16941337
24.

Delayed access to HIV diagnosis and care: Special concerns for the Southern United States.

Krawczyk CS, Funkhouser E, Kilby JM, Vermund SH.

AIDS Care. 2006;18 Suppl 1:S35-44.

25.

Factors associated with delayed initiation of HIV medical care among infected persons attending a southern HIV/AIDS clinic.

Krawczyk CS, Funkhouser E, Kilby JM, Kaslow RA, Bey AK, Vermund SH.

South Med J. 2006 May;99(5):472-81.

26.

Cost-effectiveness of enfuvirtide in HIV therapy for treatment-experienced patients in the United States.

Hornberger J, Kilby JM, Wintfeld N, Green J.

AIDS Res Hum Retroviruses. 2006 Mar;22(3):240-7.

PMID:
16545010
27.

Therapeutic immunization strategies for HIV infection.

Heath SL, Kilby JM.

Curr Opin HIV AIDS. 2006 Jan;1(1):74-81. doi: 10.1097/01.COH.0000194110.22225.86.

PMID:
19372788
28.

Salmonella infections in the setting of AIDS: a serpentine course.

Kilby JM.

South Med J. 2005 Nov;98(11):1066-7. No abstract available.

PMID:
16351025
29.

Therapeutic potential of blocking HIV entry into cells: focus on membrane fusion inhibitors.

Kilby JM.

Expert Opin Investig Drugs. 1999 Aug;8(8):1157-70.

PMID:
15992142
30.

Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection.

Betts MR, Exley B, Price DA, Bansal A, Camacho ZT, Teaberry V, West SM, Ambrozak DR, Tomaras G, Roederer M, Kilby JM, Tartaglia J, Belshe R, Gao F, Douek DC, Weinhold KJ, Koup RA, Goepfert P, Ferrari G.

Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4512-7. Epub 2005 Mar 7.

31.

CD8 T-cell responses in early HIV-1 infection are skewed towards high entropy peptides.

Bansal A, Gough E, Sabbaj S, Ritter D, Yusim K, Sfakianos G, Aldrovandi G, Kaslow RA, Wilson CM, Mulligan MJ, Kilby JM, Goepfert PA.

AIDS. 2005 Feb 18;19(3):241-50.

PMID:
15718834
32.

Safety, tolerability, and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patients.

Wheeler DA, Lalezari JP, Kilby JM, Wheat J, Delehanty J, DeMasi R, Patel I, Salgo M.

J Clin Virol. 2004 Jun;30(2):183-90.

PMID:
15125875
33.

Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV.

Eron JJ, Gulick RM, Bartlett JA, Merigan T, Arduino R, Kilby JM, Yangco B, Diers A, Drobnes C, DeMasi R, Greenberg M, Melby T, Raskino C, Rusnak P, Zhang Y, Spence R, Miralles GD.

J Infect Dis. 2004 Mar 15;189(6):1075-83. Epub 2004 Mar 2.

PMID:
14999611
34.

Novel therapies based on mechanisms of HIV-1 cell entry.

Kilby JM, Eron JJ.

N Engl J Med. 2003 May 29;348(22):2228-38. Review. No abstract available.

PMID:
12773651
35.

Antibody neutralization and escape by HIV-1.

Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM.

Nature. 2003 Mar 20;422(6929):307-12.

PMID:
12646921
36.

A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy.

Lalezari JP, Eron JJ, Carlson M, Cohen C, DeJesus E, Arduino RC, Gallant JE, Volberding P, Murphy RL, Valentine F, Nelson EL, Sista PR, Dusek A, Kilby JM.

AIDS. 2003 Mar 28;17(5):691-8.

PMID:
12646792
37.

Enfuvirtide.

Chen RY, Kilby JM, Saag MS.

Expert Opin Investig Drugs. 2002 Dec;11(12):1837-43. Review.

PMID:
12457443
38.

The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.

Kilby JM, Lalezari JP, Eron JJ, Carlson M, Cohen C, Arduino RC, Goodgame JC, Gallant JE, Volberding P, Murphy RL, Valentine F, Saag MS, Nelson EL, Sista PR, Dusek A.

AIDS Res Hum Retroviruses. 2002 Jul 1;18(10):685-93. Erratum in: AIDS Res Hum Retroviruses. 2003 Jan 1;19(1):83..

PMID:
12167274
39.

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC.

Antimicrob Agents Chemother. 2002 Jun;46(6):1896-905.

41.

SIVcpz in wild chimpanzees.

Santiago ML, Rodenburg CM, Kamenya S, Bibollet-Ruche F, Gao F, Bailes E, Meleth S, Soong SJ, Kilby JM, Moldoveanu Z, Fahey B, Muller MN, Ayouba A, Nerrienet E, McClure HM, Heeney JL, Pusey AE, Collins DA, Boesch C, Wrangham RW, Goodall J, Sharp PM, Shaw GM, Hahn BH.

Science. 2002 Jan 18;295(5554):465. No abstract available.

42.

Human immunodeficiency virus pathogenesis: insights from studies of lymphoid cells and tissues.

Kilby JM.

Clin Infect Dis. 2001 Sep 15;33(6):873-84. Epub 2001 Aug 6. Review.

PMID:
11512093
43.
44.
45.

Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: A case report.

Kilby JM, Goepfert PA, Miller AP, Gnann JW Jr, Sillers M, Saag MS, Bucy RP.

Ann Intern Med. 2000 Sep 19;133(6):435-8. Review.

PMID:
10975961
46.

Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults.

Kilby JM, Sfakianos G, Gizzi N, Siemon-Hryczyk P, Ehrensing E, Oo C, Buss N, Saag MS.

Antimicrob Agents Chemother. 2000 Oct;44(10):2672-8.

47.

Stability in the HIV vDNA pool in peripheral CD4+ T cells of untreated patients by single tube quantitative PCR.

Hockett RD Jr, Saag MS, Kilby JM, Sfakianos G, Wakefield TB, Bucy RP.

J Virol Methods. 2000 Jun;87(1-2):1-12.

PMID:
10856747
49.

Images in clinical medicine. Cytomegalovirus esophageal ulcers.

Kilby JM, Singh S.

N Engl J Med. 2000 Feb 17;342(7):475. No abstract available.

50.

Evaluation of distinct blood lymphocyte populations in human immunodeficiency virus type 1-infected subjects in the absence or presence of effective therapy.

Derdeyn CA, Kilby JM, Miralles GD, Li LF, Sfakianos G, Saag MS, Hockett RD, Bucy RP.

J Infect Dis. 1999 Dec;180(6):1851-62.

PMID:
10558941

Supplemental Content

Loading ...
Support Center